Knorliii Posted - 6 days ago

$APRE

Lordraxx Posted - 6 days ago

$APRE i figure I'll break even at $100 , but goddammit I'll not sell one penny till then..even if it takes till my deathbed!

Bakeface Posted - 1 week ago

$APRE

Umeshnp Posted - 08/26/24

$APRE is this stock ever going to pop lost 60k on this junk stock still holding 37$ purchase price

Mikey9696 Posted - 08/22/24

$APRE Something good has to be coming soon. I see that institutional ownership is rising.

Lordraxx Posted - 4 weeks ago

$APRE

ReversalSwingTrading Posted - 1 month ago

$APRE is this alive again?

Torn891 Posted - 1 month ago

$APRE I said i'd ride my last small hold here to zero and it may be the first time that actually happens

Stock_Titan Posted - 1 month ago

$APRE Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update https://www.stocktitan.net/news/APRE/aprea-therapeutics-reports-second-quarter-2024-financial-results-and-bv968ttq6sm0.html

PenkeTrading Posted - 1 month ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Aprea Therapeutics Inc. Is that bullish or bearish? $APRE #APRE #nasdaq #tradingsignals #technicalanalysis

DTPantera Posted - 1 month ago

$APRE done guy's, I'm out. GLTA!! Long term tax deduction.....

NVDAMillionaire Posted - 1 month ago

$APRE Aprea Therapeutics, Inc. (NASDAQ:APRE): Advancing Synthetic Lethality Therapies with Promising Pipeline http://beyondspx.com/2024/08/02/aprea-therapeutics-inc-nasdaqapre-advancing-synthetic-lethality-therapies-with-promising-pipeline/

DTPantera Posted - 07/24/24

$APRE be more like $VKTX!!

Mikey9696 Posted - 07/23/24

$APRE $RGC

dcast Posted - 07/22/24

$APRE sure hasn't done much since breaking that downtrend.

Jbo11 Posted - 2 months ago

$APRE Broke though a pretty long downtrend.

NVDAMillionaire Posted - 2 months ago

$APRE Aprea Therapeutics, Inc. (NASDAQ:APRE): Navigating the Synthetic Lethality Landscape with Promising Pipeline http://beyondspx.com/2024/07/12/aprea-therapeutics-inc-nasdaqapre-navigating-the-synthetic-lethality-landscape-with-promising-pipeline/

RollingDollars Posted - 2 months ago

$APRE

Redline247 Posted - 2 months ago

$APRE Maybe some wisdom from your experiences here can be shared with the people in $KTRA

TickerDD_com Posted - 2 months ago

From 6/24/2024, looking back across 21 Month-Ends for APRE, Percentage Change of Average Monthly Price had More Negatives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $APRE #APRE #APREStock #TickerDD #APREPrice https://www.youtube.com/watch?v=yeb_X-QMlR0

SNOWBALLDB321 Posted - 06/27/24

$APRE THE (Key Opinion Leader) event focused on the issue of WEE1 inhibition combined with off-targeting of PLK1, which creates overlapping toxicities and actually dampens the effect of inhibiting WEE1. This is where Zentalis ran into trouble with toxicities. The lack of tox for Aprea's molecules has been demonstrated in preclinical studies and led to clinical development that is using a continuous dosing strategy, which is ideal for driving the most robust synthetic lethal (SL) phenotype. Separate Aprea from Zentalis; that is the key. Given the challenges that Merck, AstraZeneca and Zentalis have had with WEE1s, which again are nearly the same molecules, we believe Aprea may be unfairly lumped into this group. APR-1051 is a completely different molecule. FDA has seen the preclinical data and permitted the P1 to use continuous dosing. Given the activity around the WEE1 inhibition space, the efficacy is there and thus should be there for APR-1051.

SNOWBALLDB321 Posted - 06/24/24

$APRE I listened to Aprea presentation today regarding wee1. This is my summary. The presentation focused on the recent revelation of test results of aprea's competition in the Wee1 inhibition space. The 2 competitive Wee1 drugs had adverse affects on the polo-like kinase (PLK) which participates in the regulation of the cell cycle. This caused sepsis in several patients including several deaths. This caused the FDA to put a hold on these wee1 drugs. According to the Aprea team this safety issue is the main differentiation between Aprea and its competion where Aprea has demonstrated little or no adverse effects on (PLK) based on studies in mice. The Q&A session featured the 3 main analyst who are forecasting Apreas pipeline. The analyst are; Joseph Pantginis Wainwright Jason McCarthy Maxim group. Robert Driscoll from Wed bush. The response they gave to the answers to their question was positive. One Q&A in stood out to me. That a future goal is to have ATR119 & APR1051 work as a combo therapy

DTPantera Posted - 2 months ago

$APRE Has any of you legacy folks here averaged down, or are you just waiting for a pop to bail?

dcast Posted - 3 months ago

$APRE these PRs aren't being well received as far as the stock price is concerned.

Stock_Titan Posted - 3 months ago

$APRE Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 https://www.stocktitan.net/news/APRE/aprea-therapeutics-announces-first-patient-dosed-in-acesot-1051-qa9oxd24ogq7.html

DTPantera Posted - 3 months ago

$APRE how in God's green earth does a company that does zero for years stay in business??

dcast Posted - 05/29/24

$APRE maybe we'll see a little delayed run up after that news drop. maybe...

Deepsyd Posted - 05/28/24

$APRE Wow! That’s some great news….

DonCorleone77 Posted - 05/28/24

$APRE Aprea announces SRC enhances dosing of patients with ATRN-119 at 800 mg Aprea Therapeutics announced that the Safety Review Committee, SRC, overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily can commence and that Cohort 6 is open for enrollment. This decision follows review of the safety and pharmacokinetic data from patients treated at 550 mg once daily. "We are very pleased with the progress in the ABOYA-119 clinical trial and with the SRC's recent endorsement to commence dosing of patients with ATRN-119 at 800 mg once daily representing progress in ATRN-119 development," said Nadeem Mirza, M.D., M.P.H., Chief Medical Officer of Aprea. "Pharmacokinetic data show that the duration of systemic exposure substantially increases with each dose level of ATRN-119. New data reported at the recent AACR annual meeting show that plasma concentrations of the drug are entering the expected therapeutic range at dose levels of 550 mg and above. We anticipate to announce additional safety and initial efficacy data from this study in the second half of 2024 and to complete dose escalation by the fourth quarter. Overall, we are very excited by ATRN-119, which we believe is differentiated from other ATR inhibitors in selectivity and toxicity profile."

Stock_Titan Posted - 05/28/24

$APRE Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial https://www.stocktitan.net/news/APRE/aprea-therapeutics-announces-that-safety-review-committee-src-v7988ly1v3m0.html